首页> 外文学位 >Chemical stability of amorphous pharmaceuticals prepared with silicates.
【24h】

Chemical stability of amorphous pharmaceuticals prepared with silicates.

机译:用硅酸盐制备的无定形药物的化学稳定性。

获取原文
获取原文并翻译 | 示例

摘要

Poor solubility of new drug candidates resulting in low bioavailability is becoming a major problem in drug formulation development. Amorphous pharmaceuticals are being increasingly investigated to improve dissolution rate and bioavailability of poorly soluble drugs. However, physical and chemical stability issues often limit the application of amorphous systems in drug product development. Preparation of amorphous drugs using silicates, in particular, has been shown to vastly improve physical stability. However, the catalytic activity of silicates to facilitate chemical reactions may accelerate drug degradation. In this study, several factors and mechanisms affecting the chemical stability of amorphous drugs prepared with silicates (Neusilin and Aerosil) were investigated using quinapril hydrochloride (QHCl) as a model drug. Amorphous samples were prepared by cryo-grinding. The effects of pH grade of silicates, drug:silicate ratio and relative humidity (%RH) on chemical stability of the co-ground amorphous drug were determined.In conclusion, the effects of pH grade of silicates, drug:silicate ratio and %RH all contribute to the chemical stability of the amorphous drug prepared with silicates. Solid-state surface acidity measurement is the best predictor of pH-stability profiles of amorphous formulations. pH-modifiers were shown to improve chemical stability without compromising the physical stability of the amorphous formulation.The pH grade of silicates significantly affects the chemical stability of co-ground amorphous QHCl with greater degradation observed in lower pH grades of Neusilin. The addition of acidic or basic pH-modifiers influences QHCl degradation in accordance with the pH-stability profile of the drug in the amorphous state. However, the pH-stability profile of amorphous QHCl prepared with different pH grades of silicates was not consistent with the pH-stability profile of the drug in solution. A solid-state equivalent pH (pHeq) of amorphous samples was measured using diffuse reflectance spectroscopy and the results indicate that pHeq provides a more accurate prediction of the effective surface acidity and degradation of QHCl in amorphous formulations than the suspension pH. The chemical stability of co-ground amorphous QHCl was also influenced by drug:silicate ratio and %RH. The degradation of amorphous QHCl co-ground with Neusilin was low at both lower and higher percentages of Neusilin with maximum degradation observed at intermediate percentages. This effect of drug:Neusilin ratio was correlated with the pHeq of the amorphous formulation, which changes with percentages of Neusilin. Amorphous QHCl co-ground with Neusilin showed greater degradation at both lower and higher %RH with maximum stability observed at intermediate %RH. This complex relationship between degradation rate and %RH is consistent with the competitive adsorption of drug and water molecules on silicate surfaces.
机译:新候选药物的溶解性差导致生物利用度低正成为药物制剂开发中的主要问题。越来越多地研究无定形药物以改善难溶性药物的溶解速度和生物利用度。但是,物理和化学稳定性问题通常限制了无定形系统在药物产品开发中的应用。特别是,使用硅酸盐制备无定形药物已显示可大大改善物理稳定性。但是,硅酸盐促进化学反应的催化活性可能会加速药物降解。在这项研究中,使用盐酸奎尼普利(QHCl)作为模型药物,研究了影响使用硅酸盐(Neusilin和Aerosil)制备的无定形药物的化学稳定性的几种因素和机理。通过冷冻研磨制备非晶态样品。确定了硅酸盐的pH等级,药物:硅酸盐的比例和相对湿度(%RH)对共研磨无定形药物化学稳定性的影响。结论,硅酸盐的pH等级,药物:硅酸盐的比例和%RH的影响所有这些都有助于用硅酸盐制备的无定形药物的化学稳定性。固态表面酸度测量是无定形制剂pH稳定性曲线的最佳预测指标。已表明,pH调节剂可改善化学稳定性而不损害无定形制剂的物理稳定性。硅酸盐的pH等级会显着影响共研磨无定形QHCl的化学稳定性,而在较低pH等级的Neusilin中观察到降解程度更大。酸性或碱性pH调节剂的添加会根据无定形状态下药物的pH稳定性曲线影响QHCl的降解。但是,用不同pH等级的硅酸盐制备的无定形QHCl的pH稳定性曲线与溶液中药物的pH稳定性曲线不一致。使用漫反射光谱法测量了无定形样品的固态当量pH(pHeq),结果表明,与悬浮液pH相比,pHeq提供了无定形制剂中有效表面酸度和QHCl降解的更准确预测。共研磨的无定形QHCl的化学稳定性也受药物:硅酸盐比和%RH的影响。与Neusilin共同研磨的无定形QHCl的降解率在Neusilin的较低和较高百分比处均较低,在中等百分比时观察到最大降解。药物:神经胶蛋白比例的这种作用与无定形制剂的pHeq相关,该pHeq随神经胶蛋白的百分比而变化。与Neusilin共研磨的无定形QHCl在较低和较高%RH下均显示出更大的降解,在中等%RH下观察到最大的稳定性。降解速率和%RH之间的这种复杂关系与药物和水分子在硅酸盐表面上的竞争性吸附相一致。

著录项

  • 作者

    Hailu, Shumet A.;

  • 作者单位

    University of Connecticut.;

  • 授予单位 University of Connecticut.;
  • 学科 Chemistry Pharmaceutical.Chemistry Physical.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 233 p.
  • 总页数 233
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号